Business Wire

SFL

11.2.2021 19:12:12 CET | Business Wire | Press release

Share
SFL – 2020 Annual Results

Regulatory News:

SFL (Paris:FLY):

Rental income: €182.4m

EPRA earnings: €100.8m

Attributable net profit: €286.9m

Portfolio value: €7,458m

EPRA NDV: €98.8/share

The financial statements for the year ended 31 December 2020 were approved by the Board of Directors of Société Foncière Lyonnaise on 11 February 2021 at a meeting chaired by Juan José Brugera.

In a market thrown into turmoil by the Covid-19 crisis, although rental income and EPRA earnings declined, they remained robust and the portfolio’s appraisal value continued to rise along with the Company's NAV, attesting to the Group’s strategic resilience.

The auditors have completed their audit of the annual financial information and are in the process of issuing their report.

Consolidated data (€ millions)

 

 

2020

2019

Change

Rental income

182.4

198.7

-8.2%

Adjusted operating profit*

152.6

172.8

-11.7%

EPRA earnings

100.8

119.2

-15.5%

Attributable net profit

286.9

589.8

-51.4%

* Operating profit before disposal gains and losses and fair value adjustments

 

 

 

 

 

31/12/2020

31/12/2019

Change

Attributable equity

4,647

4,485

+3.6%

Consolidated portfolio value excluding transfer costs

7,458

7,158

+4.2%

Consolidated portfolio value including transfer costs

7,946

7,632

+4.1%

EPRA NNNAV

4,598

4,461

+3.1%

EPRA NDV

4,596

4,459

EPRA NDV per share

€98.8

€95.8

 

Results

Rental income

Rental income amounted to €182.4 million in 2020 versus €198.7 million the previous year, a decline of €16.3 million (8.2%):

- On a like-for-like basis (excluding changes in consolidation scope affecting period-on-period comparisons), rental income contracted by €7.0 million (3.8%). The decline was due to the effects of the Covid-19 crisis, which led to rent holidays or reductions being granted to certain tenants and to the closure of the Edouard VII and #cloud.paris conference centres as well as the Indigo hotel. Excluding these effects, the like-for-like change was an increase of €1.3 million (0.7%), reflecting higher rental income from the Washington Plaza, 103 Grenelle and Cézanne Saint-Honoré buildings.

- Rental income from units being redeveloped or renovated in the periods concerned was down by €6.2 million, due to the renovation of several floors that were vacated in late 2019 and early 2020, mainly in the 103 Grenelle and Edouard VII buildings.

- Lastly, income from various penalties was down by €3.2 million compared with 2019.

Operating profit before disposal gains and losses and fair value adjustments to investment property came to €152.6 million in 2020 versus €172.8 million the year before.

Portfolio appraisal value

The portfolio’s appraisal value at 31 December 2020 was 4.2% higher on a like-for-like basis than at 31 December 2019. The increase led to the recognition of positive fair value adjustments to investment property of €176.5 million in 2020 compared with positive adjustments of €526.9 million in 2019.

Net profit

Net finance costs stood at €34.3 million in 2020, versus €28.1 million in 2019. The year-on-year increase of €6.2 million included €3.3 million in net non-recurring costs, primarily reflecting the €4.3 million payment made on the €160.7 million worth of bonds bought back in September 2020. Recurring finance costs were €2.9 million higher, due to increases in both average debt and the average cost of debt.

After taking into account these core items, EPRA earnings came to €100.8 million in 2020. This represented a 15.5% decline compared with the previous year’s record high of €119.2 million, but was in line with the Group’s performance over the period 2016 to 2018. Attributable net profit for the year amounted to €286.9 million, versus €589.8 million in 2019.

Business review

Rental operations

The Covid-19 crisis caused the Paris region rental market to contract by 45% compared with 2019. SFL bucked the trend, however, signing leases on some 23,000 sq.m. The main leases concerned:

- 83 Marceau: entire building pre-let to Goldman Sachs and Bryan Garnier;

- Cézanne Saint-Honoré: lease on 2,600 sq.m. signed with Quartus;

- Edouard VII: new lease with Olympia, representing 6,000 sq.m.;

- 112 Wagram: lease on 975 sq.m. signed with Sony Interactive.

Nominal office rents for leases signed in 2020 averaged €846 per sq.m., with effective rents averaging €717 per sq.m. for an average non-cancellable term of 7.2 years, reflecting the very high quality of SFL’s buildings.

In addition to these new leases, existing leases on around 24,000 sq.m. were renegotiated or adjusted by means of addenda, in line with SFL’s policy of pro-actively managing tenant relations during the Covid-19 crisis. This focused approach helped to keep rent defaults and collection proceedings to a minimum, by talking to tenants experiencing temporary difficulties (particularly tenants of retail units) in order to find a mutually satisfactory solution.

The physical occupancy rate was 93.7% at 31 December 2020 and the EPRA vacancy rate was 6.0%. Although less favourable than the excellent end-2019 rates of 97.4% and 1.6% respectively, these rates nevertheless attest to the Group’s success in limiting the number of vacant units in revenue‑generating properties.

Development operations

Properties undergoing development at 31 December 2020 represented roughly 17% of the total portfolio. They consist mainly of the Group’s current three flagship projects concerning:

- 83 avenue Marceau (approximately 9,000 sq.m.). This building is in the process of being redeveloped, with delivery scheduled for the third quarter of 2021, and has been fully pre-let.

- The Biome office complex on avenue Emile Zola (approximately 24,000 sq.m.). Redevelopment work continued at a brisk pace in 2020 and will be delivered in mid-2022.

- The retail space in the Louvre Saint-Honoré building (approximately 20,000 sq.m.). Work to clear the space to be redeveloped began in September 2020 and delivery is scheduled for 2024 under the turnkey lease signed with the Cartier Foundation.

These three development programmes were pursued in 2020 with only limited disruption during the first lockdown from March to May.

Similarly, refurbishment work on vacant units in other buildings (including Washington Plaza, 103 Grenelle and Edouard VII) also continued and the units were delivered under favourable conditions after minimal disruption during lockdown.

Capitalised work carried out in 2020 amounted to €111 million.

Portfolio operations

No properties were purchased or sold during 2020.

As part of its asset rotation policy, in the fourth quarter of 2020 the Group began seeking buyers for the 112 Wagram and 9 Percier properties.

The fair values of these two assets at 31 December 2020, corresponding to the price at which the property was sold (112 Wagram) or the sale was agreed (9 Percier) in January 2021, reflected a 16% average gain versus their appraisal values at 31 December 2019. This outstanding performance confirms the quality of SFL’s assets and strategic positioning.

Financing

In May 2020, SFL issued €500 million worth of 1.50% seven-year bonds due on 5 June 2027.

In addition, a new five-year €150 million revolving line of credit was obtained from BNP Paribas. This new facility cancelled and replaced a previous €150 million revolving line of credit that was reduced to €100 million in 2019 and was due to expire in May 2021.

In September 2020, an offer was launched to buy back two bond issues due in November 2021 and November 2022 respectively. At the close of the offer period, on 8 September 2020, bonds with an aggregate face value of €160.7 million had been tendered to the offer, including €100.3 million worth of bonds due in 2021 and €60.4 million due in 2022.

These operations have extended the average maturity of the Group's debt and reduced its future average borrowing costs, as part of its proactive balance sheet management strategy. The funds will be used for general corporate purposes.

Net debt at 31 December 2020 amounted to €1,890 million compared with €1,732 million at the previous year-end, representing a loan-to-value ratio of 23.8%. The average cost of debt after hedging was 1.5% at 31 December 2020 and the average maturity was 4.4 years. The interest coverage ratio at the same date stood at 5.2x.

Lastly, at 31 December 2020, SFL had €1,040 million in undrawn lines of credit.

Net asset value

The consolidated market value of the portfolio at 31 December 2020 was €7,458 million excluding transfer costs, a like-for-like increase of 4.2% from €7,158 million at 31 December 2019 that was mainly due to:

- the value created by work on the Group’s redevelopment projects: the entire 83 Marceau property was pre-let during the year, work continued on the Biome project with only limited disruption, and work began on clearing the retail space in the Louvre Saint-Honoré property;

- the focused narrowing of investment yields on the highest quality assets observed in 2020.

The value of retail units declined, however, reflecting the less favourable outlook for market rents on these units.

The average EPRA topped-up net investment yield (NIY) stood at 2.9% at 31 December 2020, compared with 3.0% at 31 December 2019.

EPRA NDV stood at €4,596 million or €98.8 per share at 31 December 2020, an increase of 3.1% (5.8% including the dividend of €2.65 per share paid in April 2020) versus €95.8 per share at 31 December 2019.

Effective from 31 December 2020, the EPRA NAV and NNNAV ratios have been replaced by new indicators: EPRA NRV (Net Reinstatement Value), NTA (Net Tangible Assets) and NDV (Net Disposal Value). These new indicators are presented in the EPRA tables below. It is interesting to note that, in the case of SFL, EPRA NDV is not materially different from EPRA NNNAV.

Management of the Covid-19 health crisis

From the onset of the crisis and throughout the year, SFL took all necessary measures to limit the pandemic’s effects on its business and results:

- All the office buildings remained open and available for use by tenants and the necessary health protection measures deployed in the buildings’ common areas were regularly updated to comply with successive government directives.

- Management of the conference centres and the Indigo hotel focused on limiting as far as possible the effects of government-mandated closures.

- Government measures concerning very small businesses and small retail outlets were applied and tenant requests for help were managed on a case-by-case basis in order to provide them with the necessary support as far as possible.

- Property leasing activities continued in a very slow rental market.

- Agreements were signed with the general contractors working on the main redevelopment projects currently in progress.

- The Group’s financial liquidity was strengthened.

All told, the Covid-19 crisis had an €8.2 million negative impact on rental income for the year (including €6.8 million in income lost due to the closure of the Edouard VII and #cloud.paris conference centres, the Indigo hotel and the Edouard VII public car park) and a €5.4 million negative impact on net property rentals.

A citizen-based approach

To ensure business continuity while also protecting employees, all of SFL’s teams worked from home during the lockdowns and gradually returned to the office when this was possible. The home-working option meant that no employees had to be furloughed.

SFL also contributed to the collective effort to fight the pandemic by donating €550,000 to the Fondation de France’s programmes in support of hospitals and health workers, medical research and assistance for vulnerable people.

Recommended dividend

At the Annual General Meeting to be held on 15 April 2021, the Board of Directors will recommend paying a dividend of €2.10 per share.

EPRA indicators

2020

2019

EPRA Earnings (€m)

100.8

119.2

/share

€2.17

€2.56

EPRA Cost Ratio (including vacancy costs)

15.8%

13.3%

EPRA Cost Ratio (excluding vacancy costs)

14.0%

12.4%

31/12/2020

31/12/2019

EPRA NAV (€m)

4,783

4,623

/share

€102.8

€99.4

EPRA NNNAV (€m)

4,598

4,461

/share

€98.8

€95.9

EPRA NRV (€m)

5,210

5,036

/share

€112.0

€108.2

EPRA NTA (€m)

5,206

5,033

/share

€111.9

€108.2

EPRA NDV (€m)

4,596

4,459

/share

€98.8

€95.8

EPRA Net Initial Yield (NIY)

2.7%

2.7%

EPRA topped-up NIY

2.9%

3.0%

EPRA Vacancy Rate

6.0%

1.6%

Alternative Performance Indicators (APIs)

API EPRA Earnings

€ millions

2020

2019

Attributable net profit

286.9

589.8

Less:

 

 

Profit (loss) on asset disposals

-

-

Fair value adjustments to investment property

(176.5)

(526.9)

Fair value adjustments to financial instruments, discounting adjustments to debt and related costs

5.0

1.7

Tax on the above items

(7.9)

14.0

Non-controlling interests in the above items

(6.7)

40.6

EPRA earnings

100.8

119.2

API EPRA NDV

€ millions

31/12/2020

31/12/2019

Attributable equity

4,647

4,485

Treasury shares

3

8

Fair value adjustments to owner-occupied property

22

20

Fair value adjustments to fixed rate debt

(76)

(54)

EPRA Net Disposal Value (NDV)

4,596

4,459

Fair value adjustments to intangible assets

2

2

EPRA NNNAV

4,598

4,461

API net debt

€ millions

31/12/2020

31/12/2019

Long-term borrowings and derivative instruments

1,476

1,441

Short-term borrowings and other interest-bearing debt

481

393

Debt in the consolidated statement of financial position

1,957

1,834

Less:

 

 

Current account advances (liabilities)

(52)

(50)

Accrued interest, deferred recognition of debt arranging fees, negative fair value adjustments to financial instruments

0

1

Cash and cash equivalents

(15)

(54)

Net debt

1,890

1,732

More information is available at www.fonciere-lyonnaise.com/en/publications/results

About SFL

Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.5 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.) and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.

Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA

S&P rating: BBB+ stable outlook

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye